COSCIENS Biopharma Inc T.AEZS

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:AEZS - Post by User

COSCIENS Biopharma Inc > Biomaterials scientific journal

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Jun 21, 2024 11:45am

96 Views

Post# 36100062

Biomaterials scientific journal

April 29, 2024 news release:

"A comprehensive scientific article was recently submitted to the Biomaterials scientific journal."

Perplexity Ai:

"Biomaterials is a high impact journal in the field of biomaterials science. It has an impact factor of 14.0 as of 2022 (2023 update), making it the leading journal in the field with the highest impact factor."

May 23, 2023 news release from CZO:

"If these results are replicated in human trials, this treatment approach could profoundly change the landscape of fibrotic lung disease therapeutics,” added Dr. Martin Kolb, a respected Pulmonologist and Professor of Medicine at McMaster University."

In October of last year at a presentation Gilles said they had to do a short toxicology study.

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant